3-Hydroxypyridazine 1-oxides as carboxylate bioisosteres: A new series of subtype-selective AMPA receptor agonists
Neuropharmacology, ISSN: 0028-3908, Vol: 51, Issue: 1, Page: 52-59
2006
- 15Citations
- 20Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- CrossRef15
- 15
- Captures20
- Readers20
- 20
- Mentions2
- References2
- 2
Article Description
Three positional isomers (compounds 1, 2, and 3 ) of 1-uracilylalanine (willardiine) based on a 3-hydroxypyridazine 1-oxide scaffold with an alanine side-chain at positions 4 ( 1 ), 5 ( 2 ) or 6 ( 3 ) were tested for binding to recombinant homomeric AMPA receptor (AMPA-R) subtypes GluR1-4, as well for excitatory activity on the rat cortical wedge preparation. 1 had approximately 30 times higher affinity than willardiine while showing a similar selectivity profile, i.e. 22-fold selectivity for GluR1/2 over GluR3/4. The GluR1-4 affinities of 3 were similar to 1, however, its 31-fold selectivity for GluR1/2 over GluR3/4 is the highest yet observed among azine-based glutamate analogues. The non-isosteric congener 2 showed weaker binding to AMPA-Rs. In the cortical wedge, 1 evokes similar responses to AMPA, while 3 and 2 are 10- and 100-fold weaker, respectively. Dose–response curves on Xenopus lævis oocytes expressing GluR1-4( flip ) confirmed that 1 and 3 are potent GluR1/2 receptor agonists (EC 50 s from 0.26 to 1.7 μM) but are 10- to 160-fold less potent at GluR3/4. The structures, potencies and selectivities of this new class of AMPA agonists are compared with those of willardiine, 5-fluorowillardiine and azawillardiine, referring to the binding mode observed in the crystal structure of willardiine bound to GluR2-S1S2. The results indicate that the 3-hydroxypyridazine 1-oxide moiety can function as an outstanding carboxylate mimic at AMPA-Rs, leading the way to further fine-tuning of subtype selectivity. This little-explored molecular motif may find wider application in medicinal chemistry.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0028390806000402; http://dx.doi.org/10.1016/j.neuropharm.2006.02.013; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33745209653&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16631211; https://linkinghub.elsevier.com/retrieve/pii/S0028390806000402; https://dx.doi.org/10.1016/j.neuropharm.2006.02.013
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know